{"preliminary_commentary":{"by_channel":{},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"EXCALIBER-RRMM","nct_id":"NCT04975997","offer":null,"registry":{"acronym":"EXCALIBER-RRMM","arms":[{"description":"Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.","label":"Daratumumab in combination with Iberdomide and dexamethasone - Dose 1","type":"EXPERIMENTAL"},{"description":null,"label":"Daratumumab in combination with Iberdomide and dexamethasone - Dose 2","type":"EXPERIMENTAL"},{"description":null,"label":"Daratumumab in combination with Iberdomide and dexamethasone - Dose 3","type":"EXPERIMENTAL"},{"description":"Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone","label":"Daratumumab in combination with dexamethasone and bortezomib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-06-25","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":939,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Daratumumab","otherNames":["DARZALEX FASPRO"],"type":"DRUG"},{"name":"Bortezomib","otherNames":[],"type":"DRUG"},{"name":"Iberdomide","otherNames":["CC-220","BMS-986382"],"type":"DRUG"},{"name":"Iberdomide","otherNames":["CC-220","BMS-986382"],"type":"DRUG"},{"name":"Iberdomide","otherNames":["CC-220","BMS-986382"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Daratumumab","otherNames":["DARZALEX FASPRO"],"type":"DRUG"}],"last_update":"2026-04-03","lead_sponsor":"Celgene","official_title":"A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-11-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Up to approximately 5 years"},{"measure":"Minimal Residual Disease (MRD) negative Complete Response (CR) at any time","timeFrame":"Up to approximately 5 years"}],"references":[{"citation":"Lonial S, Dimopoulos MA, Gavriatopoulou M, Kim K, Min CK, Oriol A, Moreira CCC, Quach H, Qiu L, Xia Z, Schjesvold F, Casas-Aviles I, Xu Y, Hungria V, Seval GC, Fang B, Kyriakou C, Prince HM, Zhuang J, Lin HC, Mateos MV, Spicka I, Maiolino A, Vural F, Basu S, Dytfeld D, Fu C, Ho PJ, Joseph N, Low M, Pour L, Girnius S, Berdeja JG, Otero PR, Cheng Y, Amatangelo M, Hersey S, Kazanecki C, Weisskopf MB, Kyada MJ, Abad PC, Chu S, Morando J, Maciag P, Richardson PG, van de Donk NW; EXCALIBER-RRMM Investigators. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Sep 25:S1470-2045(26)00450-X. doi: 10.1016/S1470-2045(26)00450-X. Online ahead of print.","pmid":"42790445","type":"DERIVED"},{"citation":"Lonial S, Dimopoulos MA, Berdeja JG, Richardson PG, Quach H, Rodriguez-Otero P, Maciag P, Hong K, Amatangelo M, Chen M, van de Donk NWCJ. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025 Jun;21(14):1761-1769. doi: 10.1080/14796694.2025.2501920. Epub 2025 May 10.","pmid":"40346992","type":"DERIVED"}],"start_date":{"date":"2022-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","url":"https://clinicaltrials.gov/study/NCT04975997"},"report":"https://www.erudio.com/reports/excaliber-rrmm-nct04975997","schema_id":"erudio.trial_listing","schema_version":"3.0","state":"built","state_text":"A report exists for this trial.","url":"https://www.erudio.com/trials/excaliber-rrmm-nct04975997"}